跳到主要导航 跳到搜索 跳到主要内容

Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis

  • Cong Liu
  • , Milena Schönke
  • , Enchen Zhou
  • , Zhuang Li
  • , Sander Kooijman
  • , Mariëtte R. Boon
  • , Mikael Larsson
  • , Kristina Wallenius
  • , Niek Dekker
  • , Louise Barlind
  • , Xiao Rong Peng
  • , Yanan Wang
  • , Patrick C.N. Rensen
  • Leiden University
  • AstraZeneca
  • The First Affiliated Hospital of Xi’an Jiaotong University

科研成果: 期刊稿件 › 文章 › 同行评审

70 引用 (Scopus)

摘要

Fibroblast growth factor (FGF) 21, a key regulator of energy metabolism, is currently evaluated in humans for treatment of type 2 diabetes and non-alcoholic steatohepatitis. However, the effects of FGF21 on cardiovascular benefit, particularly on lipoprotein metabolism in relation to atherogenesis, remain elusive. Methods and results : Here, the role of FGF21 in lipoprotein metabolism in relation to atherosclerosis development was investigated by pharmacological administration of a half-life extended recombinant FGF21 protein to hypercholesterolaemic APOE∗3-Leiden.CETP mice, a well-established model mimicking atherosclerosis initiation and development in humans. FGF21 reduced plasma total cholesterol, explained by a reduction in non-HDL-cholesterol. Mechanistically, FGF21 promoted brown adipose tissue (BAT) activation and white adipose tissue (WAT) browning, thereby enhancing the selective uptake of fatty acids from triglyceride-rich lipoproteins into BAT and into browned WAT, consequently accelerating the clearance of the cholesterol-enriched remnants by the liver. In addition, FGF21 reduced body fat, ameliorated glucose tolerance and markedly reduced hepatic steatosis, related to up-regulated hepatic expression of genes involved in fatty acid oxidation and increased hepatic VLDL-triglyceride secretion. Ultimately, FGF21 largely decreased atherosclerotic lesion area, which was mainly explained by the reduction in non-HDL-cholesterol as shown by linear regression analysis, decreased lesion severity, and increased atherosclerotic plaque stability index. Conclusion: FGF21 improves hypercholesterolaemia by accelerating triglyceride-rich lipoprotein turnover as a result of activating BAT and browning of WAT, thereby reducing atherosclerotic lesion severity and increasing atherosclerotic lesion stability index. We have thus provided additional support for the clinical use of FGF21 in the treatment of atherosclerotic cardiovascular disease.

源语言英语
页(从-至)489-502
页数14
期刊Cardiovascular Research
卷118
期2
DOI
出版状态已出版 - 1 2月 2022
已对外发布是

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

学术指纹

探究 'Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis' 的科研主题。它们共同构成独一无二的学术指纹。

引用此